Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol in diabetic nephropathy
NCT02704494Phase 1Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Mar 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetic nephropathy (DN) comparing Resveratrol with Placebo (2 arms). Primary endpoints: Urine albumin level at 3 months and Serum creatinin at 3 months. Started Mar 2016; status: completed.
02
Drugs
resveratrol
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02704494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02704494.